Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...
FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.
Novo's Victoza and Ozempic have made GLP-1 a key part of the ... to the rest of the branded drug industry). Novo Nordisk has a broad global insulin business, but price pressure and growing ...
Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
can buy insulin products from Novo Nordisk's for no more than $35 a month over the next five years. This follows a similar settlement with manufacturers Eli Lilly and Sanofi. Ellison made the ...
Advocates stood next to Ellison as he made the announcement on Monday ... said Eli Lilly, Sanofi, and Novo Nordisk make up 95% of insulin manufacturers. She added having all three of these ...
After slowing down post-COVID, global dividend growth made a surprising ... Founded in 1923, Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that provides insulin, obesity ...
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...